Human cytomegalovirus infection causes degradation of Sp100 proteins that suppress viral gene expression

Journal of Virology

Volumn 85, Issue 22, 2011, Pages 11928-11937

  Kim, Young Eui ^a   Lee, Jin Hyoung ^a   Kim, Eui Tae ^a   Shin, Hye Jin ^a   Gu, Su Yeon ^a   Seol, Hyang Sook ^a   Ling, Paul D ^b   Lee, Chan Hee ^c   Ahn, Jin Hyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 1; NUCLEAR PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEASOME; PROTEIN SP100; PROTEIN SP100A; SUMO PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL NUCLEUS INCLUSION BODY; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIMERIZATION; ENZYME ACTIVITY; EPIGENETICS; FIBROBLAST; GENE DELETION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TRANSCRIPTION REGULATION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS MUTANT; VIRUS REPLICATION;

ANTIGENS, NUCLEAR; AUTOANTIGENS; CELLS, CULTURED; CYTOMEGALOVIRUS; GENE EXPRESSION; GENE SILENCING; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMEDIATE-EARLY PROTEINS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 5;

EID: 80655143462     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00758-11     Document Type: Article

References (57)

1. Adamson, A. L., and S. Kenney. 2001. Epstein-Barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. J. Virol. 75:2388-2399.
2. Ahn, J. H., E. J. Brignole III, and G. S. Hayward. 1998. Disruption of PML subnuclear domains by the acidic IE1 protein of human cytomegalovirus is mediated through interaction with PML and may modulate a RING fingerdependent cryptic transactivator function of PML. Mol. Cell. Biol. 18:4899-4913.
3. Ahn, J. H., and G. S. Hayward. 2000. Disruption of PML-associated nuclear bodies by IE1 correlates with efficient early stages of viral gene expression and DNA replication in human cytomegalovirus infection. Virology 274:39-55.
4. Ahn, J. H., and G. S. Hayward. 1997. The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PMLassociated nuclear bodies at very early times in infected permissive cells. J. Virol. 71:4599-4613.
5. Ahn, J. H., Y. Xu, W. J. Jang, M. J. Matunis, and G. S. Hayward. 2001. Evaluation of interactions of human cytomegalovirus immediate-early IE2 regulatory protein with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. J. Virol. 75:3859-3872.
6. Bottomley, M. J., et al. 2001. The SAND domain structure defines a novel DNA-binding fold in transcriptional regulation. Nat. Struct. Biol. 8:626-633.
7. Boutell, C., S. Sadis, and R. D. Everett. 2002. Herpes simplex virus type 1 immediate-early protein ICP0 and is isolated RING finger domain act as ubiquitin E3 ligases in vitro. J. Virol. 76:841-850.
8. Dent, A. L., et al. 1996. LYSP100-associated nuclear domains (LANDs): description of a new class of subnuclear structures and their relationship to PML nuclear bodies. Blood 88:1423-1426.
9. Dimitropoulou, P., et al. 2010. Differential relocation and stability of PMLbody components during productive human cytomegalovirus infection: detailed characterization by live-cell imaging. Eur. J. Cell Biol. 89:757-768.
10. Everett, R. D., and M. K. Chelbi-Alix. 2007. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89:819-830.
11. Everett, R. D., et al. 1998. The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms. J. Virol. 72:6581-6591.
12. Everett, R. D., C. Parada, P. Gripon, H. Sirma, and A. Orr. 2008. Replication of ICP0-null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J. Virol. 82:2661-2672.
13. Everett, R. D., M. L. Parsy, and A. Orr. 2009. Analysis of the functions of herpes simplex virus type 1 regulatory protein ICP0 that are critical for lytic infection and derepression of quiescent viral genomes. J. Virol. 83:4963-4977.
14. Everett, R. D., et al. 2006. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 80:7995-8005.
15. Greaves, R. F., and E. S. Mocarski. 1998. Defective growth correlates with reduced accumulation of a viral DNA replication protein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J. Virol. 72:366-379.
16. Gu, H., and B. Roizman. 2003. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitinconjugating enzyme UbcH5a. Proc. Natl. Acad. Sci. U. S. A. 100:8963-8968
17. Guldner, H. H., C. Szostecki, T. Grotzinger, and H. Will. 1992. IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. J. Immunol. 149:4067-4073.
18. Guldner, H. H., et al. 1999. Splice variants of the nuclear dot-associated Sp100 protein contain homologies to HMG-1 and a human nuclear phosphoprotein-box motif. J. Cell Sci. 112(Pt 5):733-747.
19. Hecker, C. M., M. Rabiller, K. Haglund, P. Bayer, and I. Dikic. 2006. Specification of SUMO1- and SUMO2-interacting motifs. J. Biol. Chem. 281:16117-16127.
20. Huh, Y. H., et al. 2008. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol. 82:10444-10454.
21. Isaac, A., K. W. Wilcox, and J. L. Taylor. 2006. SP100B, a repressor of gene expression preferentially binds to DNA with unmethylated CpGs. J. Cell. Biochem. 98:1106-1122.
22. Ishov, A. M., R. M. Stenberg, and G. G. Maul. 1997. Human cytomegalovirus immediate early interaction with host nuclear structures: definition of an immediate transcript environment. J. Cell Biol. 138:5-16.
23. Kang, H., et al. 2006. Inhibition of SUMO-independent PML oligomerization by the human cytomegalovirus IE1 protein. J. Gen. Virol. 87:2181-2190.
24. Kaspari, M., et al. 2008. Proteasome inhibitor MG132 blocks viral DNA replication and assembly of human cytomegalovirus. FEBS Lett. 582:666-672.
25. Kelly, C., R. Van Driel, and G. W. Wilkinson. 1995. Disruption of PMLassociated nuclear bodies during human cytomegalovirus infection. J. Gen. Virol. 76(Pt 11):2887-2893.
26. Knipscheer, P., et al. 2008. Ubc9 sumoylation regulates SUMO target discrimination. Mol. Cell 31:371-382.
27. Korioth, F., G. G. Maul, B. Plachter, T. Stamminger, and J. Frey. 1996. The nuclear domain 10 (ND10) is disrupted by the human cytomegalovirus gene product IE1. Exp. Cell Res. 229:155-158.
28. Krauss, S., J. Kaps, N. Czech, C. Paulus, and M. Nevels. 2009. Physical requirements and functional consequences of complex formation between the cytomegalovirus IE1 protein and human STAT2. J. Virol. 83:12854-12870.
29. Le, V. T., M. Trilling, M. Wilborn, H. Hengel, and A. Zimmermann. 2008. Human cytomegalovirus interferes with signal transducer and activator of transcription (STAT) 2 protein stability and tyrosine phosphorylation. J. Gen. Virol. 89:2416-2426.
30. Lee, H. R., et al. 2004. Ability of the human cytomegalovirus IE1 protein to modulate sumoylation of PML correlates with its functional activities in transcriptional regulation and infectivity in cultured fibroblast cells. J. Virol. 78:6527-6542.
31. Lee, J. M., et al. 2003. PIAS1 enhances SUMO-1 modification and the transactivation activity of the major immediate-early IE2 protein of human cytomegalovirus. FEBS Lett. 555:322-328.
32. Ling, P. D., et al. 2005. Mediation of Epstein-Barr virus EBNA-LP transcriptional coactivation by Sp100. EMBO J. 24:3565-3575.
33. Muller, S., and A. Dejean. 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption. J. Virol. 73:5137-5143.
34. Negorev, D. G., O. V. Vladimirova, A. Ivanov, F. Rauscher III, and G. G. Maul. 2006. Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression. J. Virol. 80:8019-8029.
35. Negorev, D. G., O. V. Vladimirova, and G. G. Maul. 2009. Differential functions of interferon-upregulated Sp100 isoforms: herpes simplex virus type 1 promoter-based immediate-early gene suppression and PML protection from ICP0-mediated degradation. J. Virol. 83:5168-5180.
36. Paulus, C., S. Krauss, and M. Nevels. 2006. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. U. S. A. 103:3840-3845.
37. Regad, T., and M. K. Chelbi-Alix. 2001. Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene 20:7274-7286.
38. Roth, M. B., A. M. Zahler, and J. A. Stolk. 1991. A conserved family of nuclear phosphoproteins localized to sites of polymerase II transcription. J. Cell Biol. 115:587-596.
39. Sadanari, H., et al. 2009. Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines. Virus Res. 142:68-77.
40. Seeler, J. S., et al. 2001. Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification. Mol. Cell. Biol. 21:3314-3324.
41. Seeler, J. S., A. Marchio, D. Sitterlin, C. Transy, and A. Dejean. 1998. Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. Proc. Natl. Acad. Sci. U. S. A. 95:7316-7321.
42. Shen, T. H., H. K. Lin, P. P. Scaglioni, T. M. Yung, and P. P. Pandolfi. 2006. The mechanisms of PML-nuclear body formation. Mol. Cell 24:331-339.
43. Sternsdorf, T., H. H. Guldner, C. Szostecki, T. Grotzinger, and H. Will. 1995. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand. J. Immunol. 42:257-268.
44. Sternsdorf, T., K. Jensen, B. Reich, and H. Will. 1999. The nuclear dot protein sp100, characterization of domains necessary for dimerization, subcellular localization, and modification by small ubiquitin-like modifiers. J. Biol. Chem. 274:12555-12566.
45. Szostecki, C., H. H. Guldner, H. J. Netter, and H. Will. 1990. Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis. J. Immunol. 145:4338-4347.
46. Tatham, M. H., et al. 2008. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 10:538-546.
47. Tavalai, N., P. Papior, S. Rechter, M. Leis, and T. Stamminger. 2006. Evidence for a role of the cellular ND10 protein PML in mediating intrinsic immunity against human cytomegalovirus infections. J. Virol. 80:8006-8018.
48. Tavalai, N., and T. Stamminger. 2011. Intrinsic cellular defense mechanisms targeting human cytomegalovirus. Virus Res. 157:128-133.
49. Tavalai, N., and T. Stamminger. 2008. New insights into the role of the subnuclear structure ND10 for viral infection. Biochim. Biophys. Acta 1783: 2207-2221.
50. Tran, K., J. A. Mahr, and D. H. Spector. 2010. Proteasome subunits relocalize during human cytomegalovirus infection, and proteasome activity is necessary for efficient viral gene transcription. J. Virol. 84:3079-3093.
51. Wasylyk, C., S. E. Schlumberger, P. Criqui-Filipe, and B. Wasylyk. 2002. Sp100 interacts with ETS-1 and stimulates its transcriptional activity. Mol. Cell. Biol. 22:2687-2702.
52. Wilcox, K. W., S. Sheriff, A. Isaac, and J. L. Taylor. 2005. SP100B is a repressor of gene expression. J. Cell. Biochem. 95:352-365.
53. Wilkinson, G. W., C. Kelly, J. H. Sinclair, and C. Rickards. 1998. Disruption of PML-associated nuclear bodies mediated by the human cytomegalovirus major immediate early gene product. J. Gen. Virol. 79(Pt 5):1233-1245.
54. Yi, H. A., et al. 2009. Cellular signals involved in cyclooxygenase-2 expression induced by human cytomegalovirus. Virus Res. 146:89-96.
55. Yordy, J. S., et al. 2004. SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion. Oncogene 23:6654-6665.
56. Yordy, J. S., et al. 2005. SP100 inhibits ETS1 activity in primary endothelial cells. Oncogene 24:916-931.
57. Zong, R. T., C. Das, and P. W. Tucker. 2000. Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies. EMBO J. 19:4123-4133.